StocksMedium•3 November 2026•
1 min read
Recursion Pharmaceuticals Reports Narrower-Than-Expected Q3 Loss
Key Facts
1Recursion Pharmaceuticals reported a quarterly loss of $0.22 per share, narrower than the estimated loss of $0.24.
2The current quarter's results show improvement compared to a loss of $0.36 per share reported a year ago.
Recursion Pharmaceuticals reported a quarterly loss of $0.22 per share for the third quarter of 2026. Zacks reported that this figure was narrower than the estimated loss of $0.24 per share, surpassing analyst consensus expectations for the period.
The current results represent an improvement over the same quarter last year, when the company reported a loss of $0.36 per share. In equity markets, RXRX closed at $3.83 on November 2, 2026, having reached a session high of $4.17 and a low of $3.78.